Table 3.

Filovirus vaccines

Knockout	Vaccine	Antigen	Vaccine virus/strain	Schedule	Dose/delivery route	Challenge post-vax^a	Challenge virus/strain	Challenge dose/route	Efficacy (survival)	Ref.
STAT1^−/−	EBOVΔVP30	Whole virus	EBOV/Mayinga	P	10⁶ FFU/IP	NA	NA	NA	NA	Halfmann et al. (2009)
STAT1^−/−	VLP	GP, NP, VP40	EBOV/Mayinga	P/B/B, 3-wk interval	10 μg/IM	40 d	EBOV/MA-Mayinga	1000 PFU/IP	0%	Raymond et al. (2011)
IFNAR^−/−	VEE VRP-EBOV GP	GP	EBOV/Mayinga	P	10⁶–10⁷ IU/SC	4 wk	EBOV/Kikwit or SUDV/Boniface	1000 PFU/IP	90–100%	Brannan et al. (2015)
	rVSVΔG/EBOV GP	GP	EBOV/Mayinga	P/B, 3-wk interval	2 × 10⁷ SRIP/IM	7 wk	EBOV/Mayinga	1000 PFU/IP	Protective^b	Lennemann et al. (2017)
		GP 7G	EBOV/Mayinga	P/B, 3-wk interval	2 × 10⁷ SRIP/IM	7 wk	EBOV/Mayinga	1000 PFU/IP	Protective^b	Lennemann et al. (2017)
		GP 7G	EBOV/Mayinga	P/B, 3-wk interval	2 × 10⁷ SRIP/IM	7 wk	SUDV/Boniface	1000 PFU/IP	Not protective^b	Lennemann et al. (2017)
		GP 7Gm8G	EBOV/Mayinga	P/B, 3-wk interval	2 × 10⁷ SRIP/IM	7 wk	EBOV/Mayinga	1000 PFU/IP	Protective^b	Lennemann et al. (2017)
		GP 7Gm8G	EBOV/Mayinga	P/B, 3-wk interval	2 × 10⁷ SRIP/IM	7 wk	SUDV/Boniface	1000 PFU/IP	Not protective^b	Lennemann et al. (2017)
	rVSVΔG/SUDV GP	GP	SUDV/Boniface	P/B, 3-wk interval	2 × 10⁷ SRIP/IM	7 wk	SUDV/Boniface	1000 PFU/IP	Protective^b	Lennemann et al. (2017)

None of the studies reported use of adjuvant.

B, boost; FFU, focus-forming units; IM, intramuscular; IP, intraperitoneal; IU, infectious units; MA, mouse-adapted; NA, not applicable; P, prime; PFU, plaque-forming units; SC, subcutaneous; 7G, sequence was modified to eliminate the 7 N-linked glycans in the core region (receptor binding domain and glycan cap) of GP1; 7Gm8G, sequence was modified to eliminate all 15 N-linked glycans in GP1; rVSV, recombinant vesicular stomatitis virus; SRIP, single-round infectious particles.

^{a ,}

time since last vaccine dose administered.

^{b ,}

Protective efficacy based on weight loss, reported as positive or negative effect.